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Integrative gene therapy typically requires dividing cells. This requirement has been perceived as an im-
pediment for gene transfer to mature, uninjured airways where proliferation rates are very low. In diseases
such as cystic fibrosis (CF) that may be candidates for integrative gene therapy, airway cell turnover is
not known but may be increased as a result of chronic inflammation. Todetermine if cells in airway surface
epithelium and submucosal glands of CF patients proliferate at an increased rate, paraffin sections of bron-
chial segments removed from CF patients (n = 6) at the time of lung transplantation or rapid autopsy
and from non-CF patients (n = 4) undergoing lung resection or transplantation were immunostained with
PC10, a monoclonal antibody to proliferating cell nuclear antigen (PCNA), a marker of proliferating cells.
The PCNA index (percentage of nuclei immunostaining for PCNA) in CF bronchial surface epithelium
was 17.0 ± 4.6% (mean ± SEM), substantially greater than in non-Cf airways « 0.2%). Within sub-
mucosal glands, PCNA-positive cells were more prevalent in the collecting ducts of CF patients than in
those of normal subjects, but only rare mucous or serous cells were PCNA positive. These studies show
that airway epithelial cell proliferation rates can be very high in inflamed CF airways. This prevalence
of proliferating cells suggests that CF airway epithelium and submucosal gland ducts may be amenable
to gene transfer using vectors, such as retroviruses, that require cell replication for stable integrative ex-
pression. Further studies are needed to evaluate cell proliferation in CF airways with less extensive airway
injury.
A better understanding of airway epithelial cell biology is
needed to optimize gene therapy for cystic fibrosis (CF) pa-
tients. Integrative gene transfer using retroviral and other
vectors is more efficient when cells are replicating. The nor-
mal, mature airway epithelium in experimental animals has
a very slow cell turnover and hence minimal proliferation (1,
2). However, after acute injury by inhalation of noxious
agents (3, 4), epithelial cell proliferation in experimental
animals increases. Limited information about airway cell
proliferation in human subjects is available.
The standard procedures for identifying proliferating cells
depend on incorporation of labeled nucleotides, such as
tritiated thymidine or 5-bromo-2-deoxyuridine (BrdU), into
DNA during the S phase of the cell cycle. These approaches
are not easily applicable to human subjects because of the
requirement for a "labeling period." Recently, proliferating
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cell nuclear antigen (PCNA), a 36-kD nuclear protein that
is a cofactor for polymerase delta during replication of DNA
(5, 6), has been used as a marker of proliferating cells be-
cause its expression is cell-cycle regulated, expressed during
late G1 and S phases of the cell cycle but disappearing during
early G2. Several monoclonal antibodies are commercially
available for immunodetection of this protein in frozen and
paraffin sections of a variety of tissues.
For these studies, bronchial segments of CF and non-CF
patients undergoing lung transplantation, resection, or au-
topsy (within 3.5 h after death) were immunostained with
PC10, a monoclonal antibody to PCNA, to determine prolif-
eration rates in airway surface epithelium and submucosal
glands in CF patients and in comparable regions in non-CF
airways. Because CF airways are exposed to chronic and
recurrent injury from infection and inflammation, we hypo-
thesized that cells in airway surface epithelium and submu-
cosal glands in CF patients are more proliferative than cells
in non-CF airways and hence may be more amenable to gene
therapy than previously thought.
Materials and Methods
Tissue Preparation
Bronchial segments were dissected from lungs immediately
after surgical removal. Tissues were obtained from six CF
patients (two females, four males; mean age 23 yr, range 13
 




Patient (yr) Gender Diagnosis SwCl-* Genotype Source No.t Index (%)
Non-CF
N1 4 F Pulmonary hypertension nla nla Transplant 3-5 0.2
N2 30 M Brain death nla nla Organ donor 2 < 0.1
N3 57 F COPD nla nla Transplant 3-5 < 0.1
N4 67 M Large cell cancer nla nla Left pneumonectomy 3-5 < 0.1
CF
CF1 13 M CF 107 R53Xl? Transplant 3-5 9.6
CF2 15 M CF 112 ~F5081~F508 Rapid autopsyt 3-5 19.1
CF3 21 M CF 88 ~F508/1717-1G>A Transplant 3-5 26.2
CF4 22 F CF 100 ~F5081~F508 Rapid autopsy! 3-5 31.4
CF5 42 M CF 119 n/a Rapid autopsyt 3-5 15.5
CF6 23 F Variant CF 35§ 3849+ 10kb C>TI? Transplant 3-5 < 0.1
Definitionofabbreviations:PCNA = proliferating cell nuclear antigen; nla = not available; COPD = chronic obstructive pulmonary disease; CF = cystic fibrosis.
* Sweat chloride values (mmol/liter).
t Airway generation number: trachea = 1, lobar bronchus = 2, segmental bronchus = 3, and so forth.
t Autopsy performed immediately after death; tissue placed in fixative within 1.5 to 3.5 h after death.
§ Mean of five sweat chloride values obtained at different times.
to 42 yr) at autopsy or at the time of lung resection for lung
transplantation and from four non-CF patients (two females,
two males; mean age 40 yr, range 4 to 67 yr) undergoing
transplantation or surgery (Table 1). The bronchial segments
were intrapulmonary from airway generations 3 through 5
for all subjects except one non-CF subject (N2) , a lung donor
from whom the available segment was the extrapulmonary,
mainstem bronchus (airway generation 2). Bronchial seg-
ments were fixed in 4% paraformaldehyde for 2 h, stored in
phosphate-buffered saline with 30% sucrose for 16 h, and
embedded in paraffin blocks that were identified by a code
number. Positive control tissues included human tonsil (pro-
cessed as above) and human fetal lung at 20 wk of gestation
that was harvested within 10 min of delivery, stored in Dul-
becco's minimal essential medium for 24 h, and then fixed
and embedded as above.
Immunohistochemistry
Bronchial cross-sections (6 ~m thick) were air-dried to poly-
t-Iysine-coated slides and deparaffinized. PCNA immuno-
histochemistry was performed using the monoclonal murine
antibody PCI0 (IgG2a; DAKO, Carpinteria, CA) at a dilu-
tion of 1:200. Biotin-conjugated goat anti-mouse IgG (Cap-
pel, Durham, NC) was used as the secondary antibody, and
nonspecific staining was blocked by prior incubation with
0.5 % normal goat serum. The ABC-alkaline phosphatase
enzyme system (Vector, Burlingame, CA) with the color sub-
strate Vector Red was used to detect bound antibody. As
negative controls, adjacent sections were immunostained by
the same protocol except purified mouse IgG2a was sub-
stituted for the primary antibody, PCI0. Sections were coun-
terstained with Mayer's hematoxylin and then visualized and
photographed using a Nikon Microphot-FXA microscope.
Sections of human tonsil (positive controls) containing a pre-
dominance of proliferating cells in their germinal centers
were immunostained with each batch of airway sections to
ensure technical reproducibility of staining results.
Morphologic Evaluation and Morphometry
Paraffin sections, labeled with block code number, were
examined by light microscopy at 1,000x magnification with-
out knowledge of the tissue source. At initial evaluation,
the blinded examiner (M.W.L.) noted the integrity of the
epithelium, presence of inflammatory cells, enlargement of-
submucosal glands, and dilatation of the gland duct. These
gland features are characteristic of CF airways. One sec-
tion per bronchial segment was morphometrically exam-
ined. All surface epithelial cell nuclei in the entire bronchial
cross-section were examined and classified as PCNA posi-
tive (red nuclei from Vector Red staining) or PCNA negative
(blue nuclei from hematoxylin staining). The PCNA index
(percentage of PCNA-positive nuclei) was determined from
counts of more than 1,000 cells around the entire circumfer-
ence of each bronchial cross-section. Intraepithelial, inflam-
matory cell nuclei were distinguished from epithelial cell
nuclei by their smaller size (approximately one-half to two-
thirds the size of epithelial cell nuclei) and greater intensity
of nuclear staining with hematoxylin. These intraepithelial,
inflammatory cell nuclei were not included in the cell counts.
The length of basal lamina was measured using an ocular
grid calibrated with a micrometer slide. The contour of the
basal lamina was followed as closely as possible by moving
Figure 1. Human fetal lung tissue was used as a positive control to test the PCNA immunostaining of airway epithelial cells that are prolifer-
ating during a period of rapid growth. This section from a 20-wk fetal lung demonstrates extensive proliferation of airway surface epithelial
cells in bronchi (panel a), noncartilaginous airways (panel c) and distal airways (panele), but not in negative control serial sections (panels
b, d, and f, respectively) for which mouse IgG2a was substituted for the primary monoclonal antibody, PClo. In panel a, the round cluster
of PCNA-staining cells (g) between two plates of cartilage (c) in the submucosal region is most likely a developing submucosal gland.
Magnification is the same for these photomicrographs (bar = 50 j.lm).
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the microscope stage and rotating the ocular grid. Sub-
mucosal gland duct openings were not included in the analy-
ses; the line of demarcation between epithelium and gland
duct was the point at which the basal lamina deviated more
than 45° from the established contour. Cell density (number




The airway surface of the non-CF bronchi was lined with a
pseudostratified, ciliated columnar epithelium with minimal
areas « 1% of epithelium) of disruption. In CF bronchi,
most of the epithelium was pseudostratified, ciliated colum-
nar epithelium, but there were regions of hyperplasia, squa-
mous metaplasia, and cuboidal epithelium. The epithelium
of CF bronchi was virtually continuous, with less than 5 %
of the surface disrupted or denuded. Regions of inflamma-
tory cell infiltrates were apparent within the submucosa and
epithelium of all CF bronchi but not in non-CF bronchi. The
submucosal glands in the CF bronchi, but not non-CF bron-
chi, were enlarged, with dilated gland ducts often filled with
mucus.
Airway Surface Epithelium
In the 20-wk-gestation fetal human lung (Figure 1), PCNA
immunoreactivity was prevalent in the surface epithelium of
cartilaginous, noncartilaginous, and distal airways and in the
immature submucosal glands. The PCNA staining was
specific. There was no PCNA staining in the adjacent nega-
tivecontrol sections in which immunostaining was modified
by substituting mouse IgG2a for the primary antibody. How-
ever, PCNA immunoreactivity in bronchi of mature, non-CF
airways was extremely sparse (Figure 2).
In most of the (non-CF) bronchial cross-sections, none of
the more than 1,000 surface epithelial cells were PCNA-
positive, even though numerous PCNA positive cells were
identified in other regions of the section, such as lymphoid
tissue (Figure 2b). In most of the CF bronchial sections, air-
way epithelial cell proliferation was much more apparent
than in non-CF controls. However, within a CF bronchial
cross-section, there was regional variation (Figure 3), with
areas containing rare PCNA-positive cells occurring in the
same bronchial sections as areas with multiple PCNA-
positive cells. One section contained a region of extensive
hyperplasia in which the majority of nuclei (greater than
75%) were PCNA-positive (Figure 3c). In these prepara-
tions, the resolution was not adequate to distinguish basal
cells from secretory cells; therefore, the identity of the
proliferating cells could not be determined. Many of the iso-
lated PCNA-positive nuclei (Figure 3a) were adjacent to the
basement membrane; however, in regions containing clus-
ters ofPCNA-positive cells (Figures 3b and 3c), many of the
PCNA-positive nuclei were not adjacent to the basement
membrane and, therefore, were less likely to be typical basal
cells. Infiltrating inflammatory cells, predominantly mono-
nuclear cells, were prevalent in CF epithelial and submu-
cosallayers. The nuclei of these infiltrating cells were easily
distinguished from epithelial nuclei because of their smaller
size and were not included in the cell counts.
Because of the regional variation in PCNA immunoreac-
tivity in CF bronchi, the PCNA index was determined from
cell counts in the entire circumference of the bronchial cross-
section to minimize sampling error. The PCNA index for the
CF group (17.0 ± 4.6%, mean ± SEM) was substantially
greater than for the non-CF control group (Figure 4). For
three of the four non-CF control subjects, the PCNA index
was less than 0.1%; none of more than 1,200 counted nuclei
per cross-section was PCNA positive. The PCNA index was
0.2 % in one of the four non-CF control subjects (Nl) , a 4-yr-
old undergoing lung transplantation for primary pulmonary
hypertension. For fiveofthe six CF patients, the PCNA indi-
ces ranged from 10 to 31%, but one CF bronchus had a
PCNA index less than 0.1%. At the initial microscopic in-
spection of this section, the blinded examiner noted a low
prevalence of PCNA-positive cells (as in normal airways)but
also an inflammatory cell infiltration (predominantly mono-
nuclear cells) and hypertrophied submucosal glands with di-
lated ducts. This CF patient with the low PCNA index is CF6
(Table 1), who had a variant of CF with the genotype
3849+10kb C>T and with normal sweat chloride values. In-
terestingly, this patient had delayed onset of lung disease
(first respiratory illness noted at 5 yr of age), delayed diagno-
sis (at 10 yr of age), delayed acquisition of Pseudomonas
(sputum culture at 10 yr isolated Staphylococcus aureus but
not Pseudomonas), but severe, end-stage lung disease by 23
yr of age (with forced vital capacity at 26 % of predicted,
forced expiratory volume in 1 s at 12% of predicted, and
midmaximal expiratory flow at 9 % of predicted).
Despite the differences in prevalence of proliferating
cells, the mean cell density in the CF bronchi was not
significantly different from that in control bronchi (Figure
4); however, the cell density was more variable in the CF
bronchi, most likely reflecting areas of hyperplasia and epi-
thelial shedding.
PCNA Staining in Submucosal Glands
In non-CF submucosal glands, PCNA immunoreactivity
was minimal; however, in CF glands, PCNA-staining cells
were prevalent in the gland ducts and tubules but less preva-
lent in the acini containing mucous cells (Figure 5). Infil-
trates of inflammatory cells, predominantly mononuclear
cells, were apparent around CF, but not non-CF, submucosal
glands.
Figure 3. In most of the CF bronchial sections, airway epithelial cell proliferation was much more apparent than in non-CF controls. In
a single cross-section, regions with little PCNA staining were adjacent to areas with prevalent PCNA staining. Panels a and b reflect the
variation in prevalence and intensity of PCNA staining (small arrows mark less intensely stained nuclei) as well as the marked infiltration
of inflammatory cells (arrowheads) into the epithelial and submucosal layers and thickened basal lamina (BL). In the one region of exten-
sive hyperplasia (panel c), the prevalence of PCNA-positive nuclei was greater than 75%. The negative control serial section is shown
in panel d. Magnification is the same for these photomicrographs (bar = 50 j.l.m).
 
Figure 2. Epithelial cell proliferation in bronchi from non-CF
lungs was extremely limited. No PCNA-staining bronchial epithe-
lial cells were present in several cross-sections that contained more
than 1,000 cells. Panel a is a representative section of a non-CF
bronchus that contains no PCNA-staining cells. Panel b (at a lower
magnification) demonstrates no PCNA staining in the surface epi-
thelium but a cluster of PCNA-staining cells (between arrowheads)
in the lymphoid tissue in the submucosal region. Bar = 50 JLm.
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Figure 4. Cell proliferation rates in human bronchial epithelium.
The PCNA index is the number of PCNA-positive nuclei divided
by the total number of nuclei. More than 1,000 nuclei were counted
per section. The epithelial cell density was determined from the
number of nuclei per millimeter of basallamina.
Discussion
This study uses PCNA immunostaining to assess airway epi-
thelial cell proliferation in CF and non-CF patients. Expres-
sion of PCNA is limited to late Gl and S stages with disap-
pearance during early G2 (7-9); therefore, presence of this
antigen identifies cells that are preparing for mitosis. Most
of the previous studies to identify proliferating cells in air-
wayshave used tritiated thymidine or BrdU labeling to iden-
tify cells that were in the S phase of the cell cycle at the time
of labeling. Consistent with these expected differences in ex-
pression of these markers during the cell cycle, dual-stain
comparisons ofPCNA and BrdU labeling have demonstrated
that the overlap in staining is incomplete and the proportion
of cells that are PCNA positive tends to be larger than the
proportion that are BrdU positive (10-12).
The major advantage of the PCNA immunostaining over
BrdU or tritiated thymidine incorporation is the elimination
of a "labeling period," thereby allowing application to human
tissues (including archival tissues). The major disadvantage
of PCNA immunostaining is the variable intensity and uni-
formity of PCNA immunostaining that presumably reflects
differences in expression during the cell cycle (less intense
in late Gl as expression is increasing and in early G2 as ex-
pression is decreasing but most intense during S phase) (7).
For this study, we counted all immunostained nuclei to elim-
inate subjective assessment of staining intensity. Also, the
immunoreactivity with the PCI0 antibody may be influenced
by fixation and processing conditions (13). Factors that can
decrease PCNA immunoreactivity include prolonged fixa-
tion, exposure to elevated temperatures (e.g., baking sec-
tions onto slides), and types of fixative (11, 13). For this
study, we limited the exposure to paraformaldehyde and to
heat and included positive control sections of human tonsil
to assess and ensure technical reproducibility of immuno-
staining.
Previous use of PCNA immunostaining in human lung
has focused on assessment of cell proliferation in lung neo-
plasms or bronchial epithelial dysplasia (14-16). In a study
of non-small cell carcinomas, the PCNA index was in-
creased (mean 53.4%, range 0.1 to 81.4%) and correlated
well with the mitotic index (number of mitoses per 1,000
cells) (15). In an analysis of normal and dysplastic bronchial
epithelium in biopsies from smokers, the PCNA index in
areas of mild dysplasia (median 12%, range 5 to 14%) was
not different from that in nondysplastic epithelium (median
2 %, range 0 to 19%) but was increased in moderate (median
37%, range 0 to 92%) and severe (median 46 %, range 0 to
96 %) dysplasia, suggesting that proliferation correlates with
severity of dysplasia (16).
Relatively little is known about PCNA staining in non-
dysplastic, non-neoplastic bronchial epithelium. Prelimi-
nary analysis of bronchial biopsies showed a range ofPCNA
labeling in different disease states, with a mean PCNA index
of 0.18% in healthy nonsmokers, 0.05% in nonsmoking asth-
matics, 2.4 % in smoking asthmatics, 12% in patients with
chronic bronchitis, and 10.5% in patients with non-small
cell lung cancer (17). These PCNA indices for healthy non-
smokers and nonsmoking asthmatics are comparable to our
values for non-CF airway epithelium « 0.1 to 0.2 %), and
the PCNA indices for chronic bronchitis are comparable to
our values for CF airways (mean 17%, range 0.2 to 31%).
Most of the available information on proliferation of ma-
ture airway epithelium is derived from studies in rats that
quantitated tritiated thymidine labeling. These studies dem-
onstrated a low prevalence of proliferating cells in rat airway
epithelium that varied with airway region (24 h labeling in-
dex of 1.0, 0.6, and 0.5 % in trachea, bronchi, and bronchi-
oles, respectively) (18). These labeling indices for normal
airway epithelium are slightly higher than our non-CF
PCNA indices. Possible explanations for this apparent dis-
crepancy include the long labeling period in the rat studies
(up to 24 h) and species variation. Increased airway epithe-
lial cell proliferation has been observed after a variety of air-
way insults in animal models. In our study, the increase in
airway epithelial cell proliferation in CF patients is compara-
ble to that seen in animal models after infection with Myco-
plasma pulmonis (19), mechanical trauma (20), or exposure
to cigarette smoke (3), nitrogen dioxide (4,21), or ozone (4,
22). Inflammatory cells and their products may contribute
to the injury and increased cell turnover, as suggested by
studies demonstrating epithelial injury and increased pro-
liferation after exposure to neutrophil elastase (23) and
studies identifying a strong relationship between epithelial
necrosis and prevalence of granulocytes in airways after
ozone exposure (24). Inflammatory cells, typically mononu-
clear cells, were prevalent in the CF airways but virtually ab-
sent in the non-CF airways examined in this study, support-
ing the notion that inflammatory cells and their products
contribute to the increased epithelial cell turnover and result-
ing increased proliferation. Interestingly, the CF patient with
the low PCNA index (0.2%) was a CF variant with the rare
genotype 3849+10kb C>T, which is associated with normal
sweat chlorides and milder lung disease than the more preva-
lent ~F508 genotype (25). Inflammatory cell infiltration was
apparent in airway sections of this variant CF patient, raising
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Figure 5. In submucosal glands of CF patients, PCNA-positive cells were prevalent at the duct openings shown in panel a, in dilated ducts
(d) shown in b, and in tubules (I) shown in panel c, but not in the acini (a) of CF glands (panels a and c). In non-CF glands (panel d), PCNA-
positive cells were not apparent. The magnification of photomicrographs in panels a through c is thesame; however, a higher magnification
is shown in panel d (bar = 50 p,m).
the possibility of genetic influences on epithelial responses
to inflammatory cells and their products.
A variety of factors may influence proliferation, including
age, gender, and inflammatory cell influx. The small num-
bers of subjects limit our ability to subgroup patients to ana-
lyze the specific influence of these factors. For the control
group, the youngest patient (4 yr of age) had the higher
PCNA index (0.2%), suggesting that the epithelium in im-
mature airways may be slightly more proliferative than in
mature airways. For the CF group, there was no distinct age
or gender relationship. As suggested above, the degree of
inflammation may influence proliferation. A more definitive
characterization of the relationship between inflammmation
and proliferation will require morphometric analyses to
quantitate prevalence of both neutrophil and PCNA-positive
cells in a larger group of CF patients.
These studies demonstrating enhanced proliferation of
airway epithelial cells in CF impact on strategies for gene
transfer in this patient population. Approaches using integra-
tive vectors, such as retroviruses, were initially considered
to have high potential because of the likelihood of prolonged
expression of the integrated transgenes but were discounted
because the efficiency of these integrative vectors is limited
in slowly replicating cells, as in the normal airway epithe-
lium. The increased proliferation in inflamed CF airways
provides evidence to support the use of integrative vectors
in some patients. Previous studies have demonstrated that the
chloride transport defect in CF airway epithelial cells can be
normalized when as few as 6 to 10% of the cells in an epithe-
lial sheet have been "corrected" by gene transfer (26). Our
studies suggest that there are airway regions in CF airways
in which more than 10% of the cells are proliferating and
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hence susceptible to correction by vectors that are highly
efficient in replicating cells. Key issues to be addressed are
whether these proliferating cells are accessible to vectors
that are applied to the airway lumen and whether these
proliferating cells will differentiate into cells expressing cys-
tic fibrosis transmembrane conductance regulator (CFTR).
The subpopulation of cells in the submucosal glands that are
proliferating (duct cells) is particularly intriguing because
this is consistent with the localization of CFTR (27).
We conclude that in CF patients undergoing lung trans-
plant because of severe lung disease, airway epithelial cells
and submucosal duct cells are more proliferative than in non-
CF airways. This increase in proliferation most likely reflects
injury from chronic infection and inflammation. We specu-
late that this profuse level of proliferation should be adequate
for effective gene therapy using retrovirus or adenovirus-
associated virus (AAV) vectors. Further studies are needed
to define cell proliferation at earlier stages of CF lung dis-
ease.
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